RVXCF (Resverlogix) Short-Term Debt : $0.77 Mil (As of Sep. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Resverlogix Short-Term Debt?

Resverlogix's Short-Term Debt for the quarter that ended in Sep. 2024 was $0.77 Mil.

Resverlogix's quarterly Short-Term Debt declined from Mar. 2024 ($6.75 Mil) to Jun. 2024 ($0.77 Mil) but then increased from Jun. 2024 ($0.77 Mil) to Sep. 2024 ($0.77 Mil).

Resverlogix's annual Short-Term Debt increased from Dec. 2021 ($5.97 Mil) to Dec. 2022 ($6.05 Mil) and increased from Dec. 2022 ($6.05 Mil) to Dec. 2023 ($6.71 Mil).

Resverlogix Short-Term Debt Historical Data

The historical data trend for Resverlogix's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix Short-Term Debt Chart

Resverlogix Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

14.77

11.45

5.97

6.05

6.71

Resverlogix Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Short-Term Debt	Get a 7-Day Free Trial															6.66	6.71	6.75	0.77	0.77

Resverlogix Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Resverlogix Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Resverlogix's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Resverlogix Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (OTCPK:RVXCF) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

0VF9:UK RFS:Germany RVX:Canada

Address

4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1

Website

https://www.resverlogix.com

Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.